Provided by Tiger Fintech (Singapore) Pte. Ltd.

NeuroPace Inc.

8.51
-0.2500-2.85%
Post-market: 8.930.4200+4.94%17:52 EDT
Volume:110.59K
Turnover:954.58K
Market Cap:279.12M
PE:-10.27
High:8.78
Open:8.74
Low:8.49
Close:8.76
Loading ...

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

GlobeNewswire
·
30 Jul

NeuroPace (NPCE) Receives a Buy from Leerink Partners

TIPRANKS
·
26 Jun

Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
25 Jun

NeuroPace Appoints New CFO Amid Strategic Shift

TIPRANKS
·
25 Jun

NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed

TIPRANKS
·
25 Jun

BRIEF-NeuroPace Says Rebecca Kuhn Departs As CFO, To Serve In Advisory Role

Reuters
·
25 Jun

Press Release: NeuroPace Announces Strategic CFO Transition

Dow Jones
·
25 Jun

Cantor Fitzgerald Remains a Buy on NeuroPace (NPCE)

TIPRANKS
·
16 Jun

NeuroPace Inc. Conducted Annual Stockholders' Meeting Virtually

Reuters
·
13 Jun

UBS Reaffirms Their Buy Rating on NeuroPace (NPCE)

TIPRANKS
·
12 Jun

Analysts Offer Insights on Healthcare Companies: MAIA Biotechnology, Inc. (MAIA) and NeuroPace (NPCE)

TIPRANKS
·
09 Jun

BRIEF-Neuropace Inc - Enters Into Credit Agreement With Midcap Funding Iv Trust

Reuters
·
05 Jun

Press Release: NeuroPace Secures Up to $75 Million in Debt Financing

Dow Jones
·
05 Jun

Cantor Fitzgerald Sticks to Their Buy Rating for NeuroPace (NPCE)

TIPRANKS
·
02 Jun

NeuroPace Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 May

Buy Rating for NeuroPace: Strong Revenue Growth and Efficacy of RNS System Drive Investment Appeal

TIPRANKS
·
28 May

NeuroPace initiated with a Buy at H.C. Wainwright

TIPRANKS
·
28 May

Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential

TIPRANKS
·
28 May

NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback

TIPRANKS
·
27 May

Leerink says NeuroPace results disappointing, sees hope on totality of data

TIPRANKS
·
27 May